etherna immunotherapies NV ("etherna"), a technology platform leader pioneering mRNA and lipid-based nanoparticle (LNP) technologies, announces a strategic collaboration with Dropshot Therapeutics ...

Then there’s Etherna, a Belgium- and Boston-based biotech formed in 2013 that touts both mRNA and LNP technologies. In 2022, the company raised a 39 million euro series B2 round that included ...

NIEL, Belgium and BOSTON, Jan. 9, 2025 /CNW/ -- etherna immunotherapies NV ("etherna"), a technology platform leader pioneering mRNA and lipid-based nanoparticle (LNP) technologies, announces a ...

Almirall, S.A. (ALM), a global pharmaceutical company focused on medical dermatology, and etherna, an mRNA/LNP technology platform company, announced ...

Almirall has partnered with etherna for the development of mRNA-based therapies for the treatment of severe skin diseases, including nonmelanoma skin cancer, the companies announced in a press ...

Dr. Florence Lambolez, director Pharmacology at eTheRNA, stated, "In our newly developed LNPs,the mRNAs encoding therapeutic proteins are protected against degradation during their intratumoral ...

The positions in the table below reflect the eTheRNA immunotherapies NV's position overall, domestically, within their sector, and in various subject areas based on their Share. Each position ...

etherna, a leading mRNA technologies company, today announced the appointment of Antonin (Tony) de Fougerolles as Chair. Tony has served as an Independent Board Member since January 2023.

etherna immunotherapies NV ("etherna"), a technology platform leader pioneering mRNA and lipid-based nanoparticle (LNP) technologies, announces a strategic collaboration with Dropshot Therapeutics ...

eTheRNA immunotherapies NV, Belgium Time frame: 1 June 2023 - 31 May 2024 Profile ...